Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

On November 8, 2022 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported the appointment of John F. Neylan, III, MD, as Executive Vice President, Chief Medical Officer (Press release, Akari Therapeutics, NOV 8, 2022, View Source [SID1234623499]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted that John is joining the Akari management team as Executive Vice President, Chief Medical Officer at this important stage of our company. He brings an impressive track record of successful regulatory filings and approvals to Akari as we rapidly advance our Phase 3 clinical trial of nomacopan in HSCT-TMA and our pre-clinical research of PAS-nomacopan in geographic atrophy," said Rachelle Jacques, President and CEO of Akari. "John’s proven leadership, deep clinical development background, and extensive transplant experience strengthen our clinical development efforts and support the progress of our late and early-stage programs."

Dr. Neylan has more than 20 years of experience in medical, clinical development, and R&D. Before joining Akari, he was Executive Vice President, Chief Medical Officer and Head of Research for Angion Biomedica Corporation, where he led the development of therapies for chronic fibrotic conditions of the lung and kidney, and acute organ injuries. Previously, he was Senior Vice President and Chief Medical Officer for Keryx Biopharmaceuticals and Senior Vice President, Clinical Development for Genzyme Corporation, where he headed up therapeutic development for specialty metabolic diseases including renal, cardiovascular, endocrine, and osteoarthritis indications. Dr. Neylan was the Vice President, Research & Development at Wyeth Research where he led development of transplant immunosuppressants, antivirals/antibacterials, antiarrhythmics, chemotherapeutics, and hemophilia factor replacements. He also served on multiple advisory committees for the FDA.

"I am excited to join Akari’s mission to develop nomacopan in severe pediatric HSCT-TMA and geographic atrophy, and I look forward to working with the medical community as they do their important work in these areas," said Dr. Neylan, Executive Vice President, Chief Medical Officer of Akari. "I share the urgency and passion to rapidly advance nomacopan on behalf of patients who are in desperate need of an approved treatment option."

Dr. Neylan was a Professor of Medicine at Emory University and Medical Director of the Emory Renal Transplant Program. He was an Assistant Professor of Medicine at University of California, Davis and Medical Director of the USD Renal Transplant Program. He completed a clinical fellowship in Nephrology and a research fellowship in Transplantation and Immunogenetics at Brigham & Women’s Hospital, Harvard University. Dr. Neylan completed his Internal Medicine residency at Vanderbilt University and received his M.D. from Rush Medical School.

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

On November 8, 2022 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, reported Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights (Press release, Calithera Biosciences, NOV 8, 2022, View Source [SID1234623498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants who wish to join the conference call by telephone can use this link to register and receive the dial-in numbers and unique PIN to access the call. The conference call registration and live audio webcast can be accessed via the Investors section of the Company’s website at www.calithera.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.

CTI BioPharma to Present at Upcoming November Conferences

On November 8, 2022 CTI BioPharma Corp. (NASDAQ: CTIC) reported that management will provide a corporate overview at two upcoming investor conferences in New York and London (Press release, CTI BioPharma, NOV 8, 2022, View Source [SID1234623497]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Event: Stifel Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 1:15 p.m. ET

Event: Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Time: 10:50 a.m. ET/3:50 p.m. GMT

Both presentations will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

GlycoMimetics to Participate in Two Upcoming Investor Conferences

On November 8, 2022 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that management will participate in two upcoming investor conferences (Press release, GlycoMimetics, NOV 8, 2022, View Source [SID1234623496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Stifel 2022 Healthcare Conference on November 15, 2022 – management will attend and host 1×1 investor meetings.

The Jefferies London Healthcare Conference on November 17, 2022 at 10:50 a.m. EST – management will participate in an in-person fireside chat.

An archived recording of the Jefferies fireside chat will be available for 90 days on the GlycoMimetics website at View Source

MEDIGENE PRESENTS NEW DATA ON REPRODUCIBLE PRODUCTION OF TCR-T CELLS FROM MDG1011 PROGRAM

On November 8, 2022 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of differentiated TCR-T therapies for cancers, reported that new data on reproducible production of TCR-T cells from elderly hematologically-challenged patients with blood cancers at the Cell UK Conference taking place November 7-8, 2022 in London (Press release, MediGene, NOV 8, 2022, View Source [SID1234623454]). The presentation can be found on Medigene´s website: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MDG1011 is an autologous TCR-T therapy specific for a peptide fragment of PRAME (PReferentially expressed Antigen in MElanoma), a tumor antigen presented on cancer cells by human leukocyte antigen HLA-A2. Generation of MDG1011 in the phase I dose escalation trial (NCT03503968) was complicated by numerous factors impacting the potential quality of T cells, including that patients suffered from blood cancers, were heavily pretreated, and were mostly elderly. Leukemia blasts were detected at high levels in the blood of several patients during the leukapheresis process performed to obtain the starting patient-specific T cells for MDG1011 manufacture, which had the potential to hinder the production and the final purity of MDG1011 drug products. Despite this, a success rate of 92% was achieved in production of TCR-T cells for twelve of thirteen patients using a semi-automated modular manufacturing process. Assessment of immune reactivity demonstrated high antitumor activities for all final MDG1011 products, as potential markers of potency.

Generation of MDG1011 and functional activity

Patients underwent leukapheresis and CD8-positive T cells were enriched and cryopreserved for use in generation of MDG1011 drug products. Following thawing and activation, the PRAME-specific T cell receptor was introduced into CD8-positive T cells via retroviral gene transfer. TCR-T cells were expanded and cryopreserved for later shipment to the clinical centers for thawing and application to the patients as a single infusion. The GMP processes of drug product manufacture and quality control, with subsequent immune assessments of thawed MDG1011 products demonstrated:

* Generation of highly-enriched CD8-positive TCR-T cells was successful, despite high variability in the patient leukapheresis starting materials, with no detection of residual blood cancer cells in final MDG1011 products
* TCR-T cells expressing the PRAME-specific TCR were produced in the required numbers needed for a dose escalation phase I study of MDG1011
* MDG1011 showed high viability through all steps of the process, including before and after cryopreservation
* Poly-functional cytokine secretion and killing capacity for tumor cell lines was seen with all MDG1011 products upon antigen-specific stimulation in vitro directly after thawing
* Diverse subsets of T cells were retained during the manufacturing process of MDG1011 products, including stem cell memory T cells, central memory T cells and other effector memory T cells

Overall, highly successful generation of MDG1011 was feasible for hematologically-challenged patients. The TCR-T cells displayed excellent viability after thawing and antigen-specific poly-functional cytokine secretion was observed for all MDG1011 products manufactured from such patients.

Prof. Dolores Schendel, Chief Scientific Officer at Medigene: "The production of functionally potent MDG1011 product is critical to achieve tangible clinical benefit in patient treatment. We are pleased by this achievement with a very high success rate for MDG1011 products developed for elderly patients with relapsed or refractory blood cancers. This robust process yielded high purity, high quality poly-functional CD8-positive TCR-T cells and the lessons learned here with liquid tumors provide important insights as we develop novel TCR-T therapies for patients with solid cancers."